Teprasiran

Drug Profile

Teprasiran

Alternative Names: AKIi-5; DGFi; I-5NP; QPI-1002; QPI002

Latest Information Update: 07 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Quark Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action RNA interference; Tumour suppressor protein p53 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Delayed graft function
  • New Molecular Entity No

Highest Development Phases

  • Phase III Delayed graft function
  • Phase II Acute kidney injury

Most Recent Events

  • 28 Jul 2017 Quark Pharmaceuticals completes a phase II trial in Acute kidney injury (In the elderly, In adults, Prevention) in USA, Canada and Germany (IV) (NCT02610283)
  • 28 Jul 2017 Adverse events data from a phase II trial in Acute kidney injury released by Quark Pharmaceuticals ,
  • 01 Dec 2015 Phase-II clinical trials in Acute kidney injury (Prevention) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top